At a glance
How are perimenopause, menopause and postmenopause different?
Perimenopause is the transition towards menopause. Natural menopause is usually identified after 12 months without a period when hormonal contraception is not being used. Postmenopause is the time afterwards.
Why does vitamin D remain relevant after menopause?
Lower oestrogen can increase bone turnover, the process of removing and replacing bone. Vitamin D helps the body absorb calcium and regulate bone minerals. It does not replace oestrogen or prevent every cause of bone loss.
Does vitamin D treat menopausal symptoms?
Its normal biological roles do not establish that extra vitamin D relieves hot flushes, sleep problems or mood changes. Those treatment questions require evidence from clinical studies, rather than an assumption based on cell pathways.
Read the full article below ↓How vitamin D participates in the biology of the post-reproductive transition
Menopause marks the end of menstrual periods due to loss of ovarian follicular activity. In the usual assessment of natural menopause, it is identified after 12 months without a period when hormonal contraception is not being used. Perimenopause is the transition leading up to menopause; postmenopause is the time afterwards. This page mainly concerns postmenopausal physiology. Vitamin D remains involved in mineral regulation and cellular signalling during these stages.
Menopause is a normal life stage with variable effects on symptoms and health. Lower ovarian hormone production changes the conditions in which tissues function. Vitamin D remains important for calcium and bone physiology, but broader proposed roles should not be presented as proof of improved postmenopausal resilience.
What menopause represents biologically
The menopausal transition and postmenopausal life involve changes across several systems, including
• sustained reduction in oestrogen and progesterone production
• altered hypothalamic and pituitary feedback signalling
• changes in bone turnover and mineral handling
• gradual shifts in immune balance and inflammatory tone
• long-term changes in body composition and energy regulation
These shifts are not isolated. They form an integrated re-programming of endocrine and tissue-level signalling. Vitamin D participates within this re-programming as part of the body’s wider endocrine communication network.
Vitamin D as a regulatory hormone after menopause
Vitamin D functions as a steroid-like signalling molecule rather than a conventional vitamin. After menopause it continues to bind to vitamin D receptors in bone, muscle, immune cells, and the nervous system. Through these receptors, vitamin D influences gene expression patterns involved in tissue maintenance, immune tolerance, and metabolic coordination.
This signalling remains part of the broader hormonal regulation framework that governs how tissues interpret and respond to changing internal conditions. Even when ovarian hormones decline, vitamin D helps maintain the coherence of these regulatory networks.
Bone turnover and mineral handling after menopause
One of the most visible biological changes following menopause is increased bone turnover. Reduced oestrogen alters how bone tissue responds to mechanical stress, calcium availability, and hormonal signals. Vitamin D participates in the systems that regulate intestinal calcium absorption, skeletal mineral exchange, and renal handling of phosphate.
These processes operate through the same mineral-regulatory loops described in calcium physiology and skeletal regulation. Vitamin D does not replace ovarian hormones, but it continues to support the regulatory environment in which bone remodelling occurs.
Neuroendocrine resetting
Menopause involves a re-calibration of the hypothalamic: pituitary axis. Hormone pulses, feedback thresholds, and neurotransmitter systems shift into new equilibrium states. Vitamin D receptors in neural tissue provide a possible route for local signalling. Their presence alone does not establish that vitamin D controls the neuroendocrine changes of menopause.
This aligns with broader neuroendocrine coordination, but a specific stabilising effect of vitamin D after menopause has not been established by receptor-localisation studies.
Muscle and tissue maintenance
Age-related changes in muscle mass and neuromuscular function often accelerate after menopause. Vitamin D participates in signalling systems that regulate muscle cell differentiation, mitochondrial activity, and neuromuscular communication.
These pathways connect with muscle physiology and mitochondrial regulation, supporting physical function and tissue resilience rather than acting as a performance enhancer.
Immune and inflammatory balance
Menopause is associated with changes in immune tone and inflammatory signalling. Vitamin D contributes to immune modulation by supporting tolerance, reducing excessive immune activation, and maintaining communication between immune cells.
These regulatory roles align with immune resilience and inflammatory signalling balance. These are context-dependent immune mechanisms, not proof of improved immune health after menopause.
Metabolic and energy regulation
Post-menopausal shifts in fat distribution, insulin sensitivity, and lipid handling reflect altered endocrine signalling. Vitamin D participates in metabolic coordination through pathways involved in glucose regulation, mitochondrial activity, and lipid metabolism.
These interactions fit within the framework of metabolic integration, where vitamin D contributes to whole-system energy balance rather than acting as a metabolic driver.
Ageing, longevity, and menopause
Ageing continues after menopause and affects many systems. Vitamin D has established roles in calcium and bone metabolism, while suggested effects on broader tissue repair and resilience after menopause remain less certain.
How menopause reshapes regulatory priorities
After menopause, ovarian hormone cycling has ended and several tissues respond to lower oestrogen exposure. This does not establish that the body has adopted a single new biological purpose, or that vitamin D improves repair and resilience in every affected tissue. Mechanistic hypotheses need to be distinguished from demonstrated effects in postmenopausal people.
Cellular sensitivity and signalling efficiency
Vitamin D responses depend on precursor availability, receptor expression and conditions within each tissue. These mechanisms may help explain differences between tissues and individuals, but clinical benefits after menopause cannot be inferred from cellular pathways alone.
Integration with connective and structural tissues
Changing oestrogen exposure and ageing can affect connective tissues. Studies of vitamin D-responsive genes may offer possible mechanisms, but these findings do not establish that vitamin D supplementation improves cartilage, fascia, vascular elasticity or tissue repair after menopause.
Interpreting postmenopausal adaptation
Menopause is a normal life stage, but its effects vary and can include symptoms and increased bone loss. Describing adaptation does not establish a single biological purpose for menopause or mean that adverse effects are absent. Vitamin D supports normal mineral physiology; its presence in other signalling pathways does not prove that supplements relieve menopausal symptoms or replace ovarian hormones.
Vitamin D within a whole-system context
Vitamin D does not cause menopause or restore ovarian hormone cycling. Its established role in calcium and bone metabolism continues, while effects on other postmenopausal systems require evidence beyond receptor expression or laboratory signalling studies.
This reflects the principle of systemic balance, in which no single hormone acts alone, and all signals operate within a network of feedback, adaptation, and long-term stability.
A randomised trial in postmenopausal women did not find an improvement in menopause-related symptoms with the calcium and vitamin D regimen tested. This result applies to that intervention and study population; it does not establish the effect of every possible regimen.
Sources and evidence boundaries
NHS. What are menopause and perimenopause?. Accessed 8 November 2026. Definitions and clinical context.
National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23, recommendations. Accessed 8 November 2026.
National Institutes of Health, Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. Accessed 8 November 2026. Vitamin D status and the limits of normal regulation.
Bikle DD. Vitamin D: Production, Metabolism, and Mechanism of Action. Endotext. Updated 2025. General cellular mechanisms, which do not by themselves establish menopause-specific clinical effects.
LeBlanc ES and colleagues. Calcium and vitamin D supplementation do not influence menopause-related symptoms: Results of the Women’s Health Initiative Trial. Maturitas. 2015;81(3):377 to 383. doi:10.1016/j.maturitas.2015.04.007.
Related reading
Analysis of the Efficacy and Safety of Weekly Calcifediol 100 µg in Vitamin D Deficient Patients
This approach aimed to evaluate the generalizability of weekly formulations across different baseline deficiency levels and, consequently, explore the potential for a simplified, standardized dosing regimen in clinical practice.
Original paper ↗Read more →Effect of regular resistance exercise, vitamin D, and calcium supplements on the bone mineral content and density in postmenopausal model of rats: An experimental study
Finally, the tail, hip, and lumbar bone mineral content, bone mineral density, bone thickness, and bone cells were evaluated in each group.
Original paper ↗Read more →Effects of Combined Exercise and Calcium/Vitamin D Supplementation on Bone Mineral Density in Postmenopausal Women: A Systematic Review and Meta-Analysis
Background: Postmenopausal osteoporosis (PMO) is a major cause of fragility fractures worldwide.
Original paper ↗Read more →Effects of Eggshell Calcium: and Vitamin D-Fortified HMR Combined with Aerobic Exercise on Bone Mineral Density in Postmenopausal Women: A Pilot Randomized Controlled Trial
Background/Objectives: Adequate calcium and vitamin D intake, along with regular physical activity, is essential for maintaining skeletal health in postmenopausal women.
Original paper ↗Read more →Serum 25-OH Vitamin D in relation to Bone Mineral Density and Bone Turnover
In this study, we aimed to assess cutoffs of 25-hydroxyvitamin D (25OHD) derived by the literature (20, 25, or 30 ng/mL) in relation to bone turnover and bone mineral density (BMD).
Original paper ↗Read more →Duration of Menopause, Rather than Primary Hyperparathyroidism Severity, Predicts Osteoporosis in Postmenopausal Women: A Pilot Study from a Spanish Reference Center
This pilot study aimed to evaluate the impact of menopause and PHPT on bone mineral density (BMD) and to explore additional clinical factors that may influence bone health.
Original paper ↗Read more →Obesity and Bone Loss at Menopause: The Role of Sclerostin
However, evidence exists that the risk of non-vertebral fractures can be increased in postmenopausal women with obesity as compared to healthy controls.
Original paper ↗Read more →Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal
The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600).
Original paper ↗Read more →Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women
This analysis included blood pressure (BP), and serum triglycerides, lipids (including apoproteins Apo1 and ApoB), adipokines, and C-reactive protein in n = 97 participants who finished with complete data points.
Original paper ↗Read more →Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
We retrospectively evaluated 189 postmenopausal osteoporosis patients treated with denosumab for 12 months.
Original paper ↗Read more →Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study
Hypercalcemia incidence was higher in patients with compared to without calcium supplementation, indicating that concomitant eldecalcitol and calcium should be carefully considered.
Original paper ↗Read more →Patterns of Non-adherence to Supplementation with Calcium and Vitamin D in Persistent Postmenopausal Women Are Similar at Start and 1 Year Later: A Qualitative Longitudinal Study
The study aim was to compare the overall adherence (OA) to supplementation with the fixed combination of calcium and vitamin D (Ca/D) in postmenopausal women at baseline and after 1 year, and to evaluate the fluctuation of the OA in individual months.
Original paper ↗Read more →Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women
We aimed to investigate weight-loss-related outcomes during intervention with low-fat dairy foods or Ca + vitamin D supplements, both as complements to hypocaloric diets.
Original paper ↗Read more →The effect of calcium and vitamin D supplementation on obesity in postmenopausal women: secondary analysis for a large-scale, placebo controlled, double-blind, 4-year longitudinal clinical trial
The purpose of the study is to detect the effect of calcium supplementation on indices of obesity and body composition.
Original paper ↗Read more →Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review
All randomised clinical trials (RCTs) comparing two or more treatments for postmenopausal osteoporosis supplemented with vitamin D and/or calcium were accessed.
Original paper ↗Read more →Association of dietary carbohydrate and fiber ratio with postmenopausal bone mineral density and prevalence of osteoporosis: A cross-sectional study
This study aimed to investigate the associations of carbohydrate to dietary fiber ratio with bone mineral density (BMD) and the prevalence of osteoporosis in postmenopausal women.
Original paper ↗Read more →Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients
The objective of this study was to evaluate the risk factors for low bone mineral density (BMD) and fractures in sarcoidosis.
Original paper ↗Read more →Calcium and Vitamin D Supplementation with and Without Collagen on Bone Density and Skin Elasticity in Menopausal Women: A Randomized Controlled Study
Background/Objectives: Menopause leads to estrogen deficiency, which negatively affects bone density, skin integrity, and hair health in women.
Original paper ↗Read more →Calcium intake in health maintenance: a systematic review
The aim was to conduct a review to update requirements and desirable or harmful health effects of Ca on the current scientific evidence.
Original paper ↗Read more →Dietary Calcium Intake in Patients Evaluated for Bone Fragility, with a Focus on Women Receiving Adjuvant Endocrine Therapy for Breast Cancer: A Single-Center Cross-Sectional Study
Patients were predominantly postmenopausal women, with severe osteoporosis (43.2%) or at risk of secondary osteoporosis (40.9%); 64.8% of patients evaluated for secondary osteoporosis were women on AET for BC.
Original paper ↗Read more →Vitamin D and Perimenopause
Explore how vitamin D relates to hormonal signalling, sleep, metabolism, and physiological regulation during perimenopause, focusing on systems-level changes rather than symptoms.
Read more →Original sources
What are menopause and perimenopause?
NHS. What are menopause and perimenopause?.
Publication details
NHS. What are menopause and perimenopause?. Accessed 8 November 2026. Definitions and clinical context.
Menopause: identification and management
National Institute for Health and Care Excellence.
Publication details
National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23, recommendations. Accessed 8 November 2026.
Vitamin D: Fact Sheet for Health Professionals
National Institutes of Health, Office of Dietary Supplements.
Publication details
National Institutes of Health, Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. Accessed 8 November 2026. Vitamin D status and the limits of normal regulation.
Vitamin D: Production, Metabolism, and Mechanism of Action
Bikle DD. Vitamin D: Production, Metabolism, and Mechanism of Action.
Publication details
Bikle DD. Vitamin D: Production, Metabolism, and Mechanism of Action. Endotext. Updated 2025. General cellular mechanisms, which do not by themselves establish menopause-specific clinical effects.
Calcium and vitamin D supplementation do not influence menopause-related symptoms: Results of the Women’s Health Initiative Trial
Published in Maturitas (2015).
Publication details
LeBlanc ES and colleagues. Calcium and vitamin D supplementation do not influence menopause-related symptoms: Results of the Women’s Health Initiative Trial. Maturitas. 2015;81(3):377 to 383. doi:10.1016/j.maturitas.2015.04.007.